[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stable-coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stable-coronary-artery-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,68,79,105,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053851","phase-1-a-study-to-see-how-ro7763505-works-and-how-safe-it-is-when-given-to-healthy-people-and-people-with-stable-heart-disease-100053851",false,"NCT07495813","A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease","A Phase I, Randomized, Double-Blind, Adaptive, Placebo-Controlled, Single- Ascending Dose and Multiple-Ascending Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of RO7763505 Following Oral Administration in Healthy Participants and Patients With Stable Coronary Artery Disease","Inclusion Criteria:\n\nPart 1:\n\n* Healthy biologically male and female participants of nonchildbearing potential or childbearing potential with no clinically relevant findings on physical examination at screening or baseline (assessed either on Day -2 or Day -1), including detailed medical and surgical history, vital signs, 12-lead electrocardiogram (ECG), hematology, blood chemistry, serology, and urinalysis\n* No suspicion of cognitive impairment\u002Fdementia as judged by the Investigator\n\nPart 2:\n\n* Myocardial infarction before the screening visit\n* Objective imaging evidence (coronary computed tomography \\[CT\\] angiography or invasive angiography) of coronary atherosclerosis Participants who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) are eligible if the procedure was done \\>6 months prior to screening\n* A diagnosis of stable CAD, defined as being on stable guideline-directed medical therapy (GDMT) if tolerated for at least 90 days prior to screening with no planned changes or scheduled interventions during the study\n* QTc of \\\u003C= 450 milliseconds (ms) as determined by a single 12-lead ECG recording. If the initial ECG result of the triplicate is exclusionary, consecutive repeat ECG results must be within the acceptable limits. In participants with a stable bundle branch block where the QRS duration is \\> 120 ms, the QTcF will be calculated as: QTcF - (QRS - 100 ms)\n\nExclusion Criteria:\n\nPart 1:\n\n* Any condition or disease detected during the medical interview\u002Fphysical examination that would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the study in the opinion of the Investigator\n* Vaccination within 28 days prior to Day 1 (non-live vaccines including influenza vaccination are permitted 14 days prior to Day 1) or planned before the end of the study. Investigators are advised to review the immunization status of participants who are considered for treatment with RO7763505 and follow local\u002Fnational guidance for adult vaccination against infectious disease as they deem relevant\n* Positive result on human immunodeficiency virus (HIV)-1 and HIV-2, hepatitis B virus (HBV) (either hepatitis B surface antigen \\[HBsAg\\] or hepatitis B core antibody \\[HBcAb\\]), hepatitis C virus (HCV) antibody test, or tuberculosis (TB)\n\nPart 2:\n\n* Individuals with New York Heart Association (NYHA) Class III or IV heart failure\n* Known or suspected immunocompromised state\n* Treatment with any investigational therapy within 28 days or within five drug-elimination half-lives (whichever is longer; or longer than either if required by local regulations; if the half-life is unknown, the 90-day period applies) prior to Day 1, calculated from the day of the follow-up from the previous study",true,"ALL","18 Years","75 Years",{"count":21,"type":22},196,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study will evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) (Part 1a), multiple ascending doses (MAD) (Part 1b), and the food effect (Part 1c) of RO7763505 in healthy adult participant. In Part 2, the safety, tolerability, PK and PD of multiple doses of RO7763505 in participants with stable coronary artery diseases (CAD).",[28,29],"Stable Coronary Artery Disease","Healthy Volunteers","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-03-31",{"date":38,"type":22},"2028-02-15",{"name":40,"class":41},"Hoffmann-La Roche","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100626104","phase-1-a-study-to-learn-about-how-safe-nitroglycerin-is-and-how-it-affects-the-body-when-taken-along-with-nurandociguat-in-people-with-coronary-artery-disease-100626104","NCT07431294","A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease","A Randomized, Placebo-controlled, Single Blind Drug-drug Interaction Study to Investigate the Influence of 0.4 mg Nitroglycerin Spray on the Safety, Tolerability and Pharmacodynamic Effects of Nurandociguat in Participants With Stable Coronary Artery Disease.","Inclusion Criteria:\n\n* Participant must be 40 to 80 years of age inclusive at the time of signing the informed consent\n* Participants with stable CAD defined by coronary artery stenosis in any of the 3 main coronary vessels greater than 50 percent documented by coronary angiography within the last 36 months or history of myocardial infarction more than 6 months prior to the screening visit\n* Estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL per min per 1.73 m2 at screening\n* Body weight greater than or equal to 60 kg and body mass index within the range greater than or equal to 18 and less than or equal to 36 kg per m2 at screening.\n\nExclusion Criteria:\n\n* Ejection fraction less than 30 percent at screening as determined by echocardiography\n* Progressive angina with symptoms of worsening of angina in the 3 months prior to the first screening examination and\u002For interventions such as revascularization by percutaneous coronary intervention and or coronary artery bypass graft during the last 3 months\n* Documented current relevant coronary stenosis greater than or equal to 90 percent in any of the main 3 coronary vessels without bypass graft\n* Significant valvular heart disease with moderate or severe aortic stenosis or any other significant stenosis any other moderate or severe valvular failures hypertrophic obstructive cardiomyopathy\n* Symptomatic carotid stenosis or transient ischemic attack or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement\n* Atrial fibrillation pacemaker defibrillator atrial ventricular block II and III\n* History of sustained ventricular tachycardia or ventricular fibrillation within 12 months prior first screening visit\n* History of CNS diseases such as seizures neurodegenerative diseases\n* Lung diseases such as COPD GOLD stage 2-4 pulmonary arterial hypertension or asthma\n* Medical disorder condition or history of such that would impair the participant's ability to participate or complete the study in the opinion of the investigator.","40 Years","80 Years",{"count":53,"type":22},36,[25],"This study is designed to find out how safe nitroglycerin is and how it affects the body when it is taken together with another medicine called nurandociguat in people who have coronary artery disease (CAD). CAD is a condition where the arteries that supply blood to the heart become narrowed or blocked, often causing chest pain or even heart attacks. Many people with CAD also have chronic kidney disease (CKD), a long-term condition where the kidneys do not work as well as they should.\n\nPeople with CAD often use nitroglycerin to help improve blood flow to the heart. Nurandociguat is a new medicine being studied to help people with CKD by widening blood vessels and improving blood flow. Both nitroglycerin and nurandociguat work in similar ways in the body, so taking them together could have a stronger effect on blood vessels. This might lead to a sudden drop in blood pressure or other side effects. The main goal of this study is to learn how safe it is to use nitroglycerin and nurandociguat together, and to understand how they interact in the body.",[28],"NOT_YET_RECRUITING","2026-06-24",{"date":60,"type":34},"2026-06-25",{"date":62,"type":22},"2026-10-01",{"date":64,"type":22},"2027-05-07",{"name":66,"class":41},"Bayer",5,{"id":69,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":71,"briefSummary":26,"conditions":72,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":78,"locationsCount":42},"100631064",{"count":21,"type":22},[25],[28,29],"2026-06-12",{"date":75,"type":34},"2026-06-15",{"date":36,"type":34},{"date":38,"type":22},{"name":40,"class":41},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":42},"100640911","local-and-systemic-macrophage-activation-in-coronary-and-peripheral-artery-disease-100640911","NCT07588295","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease","Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease: the LAST-COP Study","Inclusion Criteria:\n\n* Patients with chronic coronary artery disease;\n* Patients with no-ST elevation acute coronary syndrome;\n* Patients with chronic claudication (Rutherford II-III)\n* Patients with critical limb ischemia (Rutherford IV-V).\n\nExclusion Criteria:\n\n* Severe renal dysfunction\n* Severe valve disease\n* Advanced heart failure\n* Advanced liver disease\n* Chronic inflammatory or autoimmune disease\n* Use of antinflammatory drugs\n* Acute infection\n* Recent surgical procedures",{"count":87,"type":22},60,[89],"NA","Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between circulating monocytes and intraplaque macrophages.\n\nThis study aims to evaluate and compare the presence of macrophages and their subsequent activation within coronary and peripheral atherosclerotic lesions, and to correlate these findings with the distribution of circulating monocyte subpopulations.",[28,92,93,94],"Acute Coronary Syndromes","Critical Limb Ischemia","Intermittent Claudication","2026-05-11",{"date":97,"type":34},"2026-05-14",{"date":99,"type":34},"2024-03-18",{"date":101,"type":22},"2026-12",{"name":103,"class":104},"Maria Cecilia Hospital","OTHER",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100619724","coronary-laser-atherectomy-registry-from-an-international-taskforce-100619724","NCT07348341","Coronary Laser Atherectomy Registry From an International Taskforce","CLARIT","Inclusion Criteria:\n\nSubjects will be included if all the following criteria are met:\n\n1. Age 18 years or over\n2. Patient willing to be included in the registry\n3. Patients with stable coronary artery disease or acute coronary syndromes with de-novo or intra-stent restenosis (ISR) coronary lesions suitable to be treated with ELCA\n\n   * Non-Crossable with ICI catheter or:\n   * Crossable with ICI catheter with significant calcium score suggesting need for calcium modification based on IVUS or OCT criteria and\u002For\n   * Non-Dilatable with 1:1 NC balloon\n4. Mandated use of ICI:\n\n   * Attempted before use of ELCA or\n   * Following ELCA and any other calcium modification strategy utilized (to evaluate whether the additional modification demonstrates significant additional modification of the calcium on ICI)\n   * Final after DES implantation or prior to use of DCB\n5. Declared PCI strategy (planned use of ELCA, need for IVL\u002Fspecialty balloons\u002Falternative atherectomy and stent strategy) prior to PCI procedure\n\nExclusion Criteria:\n\n1. Pregnant or breast feeding\n2. Unable to give informed consent\n3. PCI performed without IVCI attempt\n4. No ELCA use\n5. Allergy to clopidogrel, prasugrel or ticagrelor or non-compliance\n6. Post- cardiac arrest or haemodynamic instability\n7. Participation in another trial.",{"count":113,"type":22},500,"OBSERVATIONAL","This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).",[28,92],[118,119,110,120,121],"excimer laser coronary atherectomy","ELCA","coronary artery disease","acute coronary syndromes","2026-01-08",{"date":124,"type":34},"2026-01-16",{"date":126,"type":22},"2026-04-30",{"date":128,"type":22},"2029-07-30",{"name":130,"class":41},"Ceric Sàrl",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":114,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":42},"100525591","mcg-is-clinically-applied-to-evaluate-myocardial-ischemic-function-in-patients-with-stable-coronary-artery-disease-100525591","NCT06123728","MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease","The Clinical Application of Magnetocardiography (MCG) as a Non-invasive Diagnostic Tool for Evaluating Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Stable coronary artery disease patients with a coronary CTA stenosis degree of 30% to 90%.\n3. Sign informed consent.\n\nExclusion Criteria:\n\n1. Patients diagnosed with acute coronary syndrome.\n2. Patients diagnosed with hypertrophic cardiomyopathy.\n3. Patients diagnosed with dilated cardiomyopathy.\n4. Patients with complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, and complete bundle branch block.\n5. Patients with a left ventricular ejection fraction less than 50%.\n6. Patients with chronic obstructive pulmonary disease, heart failure, kidney failure, or other serious diseases.\n7. Pregnant women.\n8. Patients with an allergy to contrast agents.\n9. The study subjects who have metal grafts that interfere with magnetic cardiogram examination.\n10. The study subjects who are unable to cooperate with magnetocardiogram examination and CTA.\n11. Patients who have undergone coronary artery bypass grafting.\n12. There are significant artifacts present in coronary CTA.",{"count":139,"type":22},291,"1 Year","The objective of this observational study is to evaluate the diagnostic effectiveness of magnetocardiography (MCG) in patients with stable coronary artery disease (SCAD) and compare it with coronary CTA (CCTA). Additionally, the study aims to determine the most suitable diagnostic index for MCG. The primary question it seeks to address is whether MCG or MCG combined with CCTA can be utilized to guide the clinical application of percutaneous coronary intervention (PCI) for coronary heart disease.",[28],[144,145,146],"stable coronary artery disease","magnetocardiography","coronary CTA","2024-06-02",{"date":149,"type":34},"2024-06-04",{"date":151,"type":34},"2023-04-19",{"date":153,"type":22},"2026-02",{"name":155,"class":104},"Nanhai Hospital, Guangdong Provincial People's Hospital"]